Category: Press & Media Coverage

Group 1000001206

Sen-Jam Pharmaceutical Joins Forces with The Global Passion Project for Transfor...

HUNTINGTON, N.Y., April 1, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is proud to sponsor and participate in The Global Passion Project’s upcoming Healthcare Investor Summit, taking place…
Read More
Eid Ashley Lauren St John Portrait 1 1

Sen-Jam Pharmaceutical Welcomes Immunology and Infectious Disease Expert Dr. Ash...

HUNTINGTON, N.Y., March 11, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is thrilled to announce the appointment of Dr. Ashley St. John, Ph.D., to its Scientific Advisory Board, further strengthening…
Read More
Compressed Mask Group 16

Sen-Jam Pharmaceutical Engages Destum Partners to Source Strategic Partnerships ...

HUNTINGTON, N.Y., Feb. 10, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement…
Read More
Mask Group (18)

Sen-Jam Pharmaceutical Answers Surgeon General’s Alarm with a New Therapeu...

HUNTINGTON, N.Y., Jan. 27, 2025 /PRNewswire/ — A newly published paper in the Global Journal of Addiction & Rehabilitation Medicine further expands on the U.S. Surgeon General’s advisory, linking frequent alcohol…
Read More
Compressed Mask Group 21

Sen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizon...

HUNTINGTON, N.Y., Jan. 22, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in innovative solutions targeting inflammation and metabolic health, proudly announces a financial and strategic…
Read More
Preliminary Positive Results 1 Scaled 1

Sen-Jam Pharmaceutical Announces Preliminary Results from Phase 2 Clinical Trial...

HUNTINGTON, N.Y., Jan. 15, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is excited to announce the preliminary results from its recently completed Phase 2 clinical trial evaluating the safety and efficacy of SJP-002C…
Read More
Encouragement Original 534082 Scaled 1 1 (1)

Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinic...

HUNTINGTON, N.Y., Jan. 14, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical, a leader in developing innovative solutions to address inflammation at its root cause, proudly announces that its flagship asset, SJP-001…
Read More
Group 1000001074

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory Care with Proprietary PAIR ...

HUNTINGTON, N.Y., Jan. 13, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is proud to announce a pivotal moment in its mission to transform the way the world heals by tackling inflammation at its source…
Read More
Mask Group (17)

Sen-Jam Pharmaceutical Announces Planned AI Initiative for Molecule Repurposing

HUNTINGTON, N.Y., Jan. 10, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical (“Sen-Jam”), a pioneer in innovative inflammatory care, today announced a planned new initiative for use of leading-edge AI tools…
Read More
Group 1000001075

A Global Voice on Hangover Science: Dr. Joris Verster Publishes New Paper on Alc...

Sen-Jam Pharmaceutical is proud to celebrate the recent publication of an insightful new paper by Dr. Joris C. Verster, one of our esteemed scientific advisors and a world-renowned expert in alcohol hangover research…
Read More

Where the Next Spark Becomes Tomorrow’s Headline

 

Our newsroom of scientists, strategists, and culture-watchers tracks the earliest pulses in biology, policy, and public conversation—translating fresh data into actionable perspective before the rest of pharma blinks. Stay tuned, stay sharp, and stay upstream with us.

Subscribe for Fresh Signals
MEDIA INQUIRIES

Media Inquiry